No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

The US president has flagged higher-than-expected tariffs of up to 250 per cent on drug imports, which is a potential blow to ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

A contract company for a fiber optics provider has hit a water line, forcing Lilly Grove Water Supply to issue a boil-water ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.